Answers are grounded in this paper and cite their sources.
With millions of patients benefiting from its therapeutic effects, mirabegron has earned its place as a cornerstone in the treatment of overactive bladder (OAB).1 However, a recent case report has documented a purported rare side effect due to mirabegron treatment: decreased central vision due to choroidal vasculopathy.2 Although this is the second time this has been reported, it is important to put this finding into perspective. Mirabegron has been prescribed worldwide for more than a decade, demonstrating a record of safety and efficacy among patients with OAB or neurogenic bladder. Yet, as with any medication, no treatment is entirely without risk. The recent report of decreased central vision was associated with mirabegron treatment. However, it is crucial to understand the rarity of this occurrence in the context of millions of patients who have taken this drug, raising the question of whether the ophthalmic event is unrelated to mirabegron treatment. In addition, this patient's medical history includes Tourette syndrome, depression, anxiety, and OAB. Even if the events are associated, it is worth considering whether the patient's other medications may have contributed to a drug interaction with mirabegron, because the literature suggests that mirabegron metabolism affects its adverse reactions.3 Many medications for Tourette syndrome or anxiety and depression interact with cytochrome P450, which is responsible for metabolizing mirabegron to its inactive products. Decreased central vision has only been documented in 2 cases. Assuming an association, the reversibility of this phenomenon once the medication is discontinued contributes to the low-risk profile. In our view, the risk (if it exists) is so minimal that it should not detract from its proven ability to improve patient outcomes. In conclusion, this case should not overshadow the safety and efficacy that mirabegron or other β-3 agonists have demonstrated over years of use.
No takes yet. Share an insight, caveat, or question.
Anis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: